Clinical Trials Advocacy Programs

Your support assists ICAN patients in programs such as The Barbara Cussler Lung Cancer Patient Advocacy Program, ICAN’s Leading Non-Small Cell and Small Cell Lung Cancer Patient Advocacy Program and NSCLC/SCLC Clinical Trials Advocacy Program for Newly-Diagnosed Patients.

Information about clinical trials at Stand Up To Cancer

Stand Up To Cancer (SU2C) recently launched a multicultural and bilingual (English and Spanish) Clinical Trials PSA campaign which aims to increase clinical trial participation across all cancer clinical trials, to ultimately help deliver more new therapies to patients.

Clinical Trials PSA - English 2 min: https://youtu.be/MCO34VJSXj0 |  Clinical Trials PSA - Spanish 2 min: https://youtu.be/3_W9YfdFBJo

Because of our generous supporters, ICAN patients involved in The Clinical Trials Advocacy Program, have access to the following information services:

  • A review and analysis of the patient's pathology report relating to TNM staging ("Tumor Node Metastasis"); review of the patient's medical history, diet, lifestyle and risk factors, current condition as well as any comorbid factors; and complete review of symptoms prior to presentation.
  • Referrals, at the patient contact's request, to medical oncologists, radiation oncologists, surgical oncologists, radiologists, interventional radiologists, anesthesiologists, and additional specialists relevant to the patient's ongoing care.
  • Referrals to support groups that may be of assistance in handling the emotional impact that cancer has on the patient and the patient's family.
  • Referrals to colon cancer-specific organizations that may be of assistance in addressing insurance issues or employment termination issues (because of diagnosis or disclosure of metastatic disease).
  • Review of the nature/amelioration of specific side effects from chemotherapy (such as nausea and neuropathy) as well as from other treatment modalities.
  • Discussion of the interaction of diet and cancer chemotherapy drugs based on recent studies.
  • Delineation of the symptoms about which the patient should alert his/her oncologist.
  • Discussion of relevant imaging technology.
  • Discussion of pain management issues and treatment options that can be addressed with the patient's medical team.
  • Explanation of the recommendations given or not given by the patient's physicians; assistance in answering the patient's questions which remain either after or between appointments with the medical team.
  • Review of the relevant radiotherapy/interventional radiology options which the patient contact, in turn, may discuss with his/her medical team.
  • Discussion of the relevance of the patient's specific immunohistochemistry and cytogenetic results to available clinical trials so that the patient may explore all options with his/her medical team.
  • Analysis of relevant colorectal cancer clinical trials options as well as the nature and purpose of clinical trials using Remission Coach®.
  • Review of relevant colon cancer-specific drugs in the anticancer pipeline.
  • Review of all relevant and complementary and alternative medicine ("CAM") avenues.
  • Review of the merits of filing a "Single Patient IND for Compassionate or Emergency Use" for a specific experimental cancer drug, if relevant to the patient's situation.
  • Exploration of options that might reduce travel costs for the patient contact, such as Corporate Angels Network, as well as ICAN supporters who have volunteered to host a clinical trials patient in a particular city.